|
|
| | MAB-CHMINACA Basic information |
| Product Name: | MAB-CHMINACA | | Synonyms: | MAB-CHMINACA;MAB-CHMINACA SOLUTION;N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide;ZWCCSIUBHCZKOY-UHFFFAOYSA-N;MAB-CHMINACA (CRM);1H-Indazole-3-carboxamide, N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-;N-[1-(Aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide | | CAS: | 1863065-92-2 | | MF: | C21H30N4O2 | | MW: | 370.49 | | EINECS: | | | Product Categories: | pharmaceutical intermediates | | Mol File: | 1863065-92-2.mol |  |
| | MAB-CHMINACA Chemical Properties |
| storage temp. | -20°C | | solubility | DMF: 5 mg/ml; DMSO: 10 mg/ml; DMSO:PBS(pH7.2) (1:1): 0.5 mg/ml; Ethanol: 1 mg/ml | | form | A neat solid |
| RIDADR | UN1230 - class 3 - PG 2 - Methanol, solution | | DEA Controlled Substances | CSCN: 7032
CSA SCH: Schedule I
NARC: No |
| | MAB-CHMINACA Usage And Synthesis |
| Description | AB-CHMINACA is an indazole-based synthetic cannabinoid (CB) that is structurally related to AB-FUBINACA (Item Nos. ISO60211 | ISO00134 | 14039), a high affinity ligand of the CB1 receptor (Ki = 0.9 nM). MAB-CHMINACA is structurally similar to AB-CHMINACA by bearing an identical cyclohexyl group; however, the isobutyl moiety is substituted with a tert-butyl group. It is a potent agonist of the CB1 receptor with a reported Ki value of 0.289 nM. This product is intended for forensic and research applications. | | Uses | N-[1-(Aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide is an impurity of MAB-CHMINACA (A105960) and 5-fluoro-ADB-PINACA, an indazole-based synthetic cannabinoid that is structurally related to AB-FUBINACA, a high affinity ligand of the central CB1 receptor. it is also used in the studies on the identification and quantitation of 5-fluoro-ADB-PINACA and MAB-CHMINACA indazole-based cannabinoids in dubious herbal products. Synthetic cannabinoids. | | References | [1] CARLIER J, DIAO X, SEMPIO C, et al. Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes[J]. The AAPS Journal, 2017, 71 2 1: 0. DOI: 10.1208/s12248-016-0037-5
[2] KOUTARO HASEGAWA. Postmortem distribution of MAB-CHMINACA in body fluids and solid tissues of a human cadaver.[J]. Forensic Toxicology, 2015, 33 2: 380-387. DOI: 10.1007/s11419-015-0272-y
[3] PIOTR ADAMOWICZ Joanna G. Acute intoxication of four individuals following use of the synthetic cannabinoid MAB-CHMINACA.[J]. Clinical toxicology (Philadelphia, Pa.), 2016: 650-654. DOI: 10.1080/15563650.2016.1190016 |
| | MAB-CHMINACA Preparation Products And Raw materials |
|